In June 2010, Neurocrine Biosciences entered into an exclusive worldwide collaboration with AbbVie (formerly Abbott) to develop and commercialize elagolix for women’s health. Under the terms of the agreement, AbbVie is responsible for future development and commercialization.
In 2018, AbbVie received U.S. FDA approval for ORILISSA® (elagolix) to treat pain associated with endometriosis. In 2020, AbbVie received U.S. FDA approval for ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) to manage heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Under the collaboration, elagolix is also being investigated for the treatment of polycystic ovary syndrome. AbbVie is responsible for all development, marketing and commercialization costs and Neurocrine Biosciences is entitled to a royalty on worldwide sales of ORILISSA, ORIAHNN and any other product containing elagolix.
Mitsubishi Tanabe Pharma
In March 2015, Neurocrine Biosciences entered into an exclusive collaboration and licensing agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of valbenazine for movement disorders in Japan and other select Asian markets.
Mitsubishi Tanabe will be responsible for all development, marketing and commercialization costs in their territories and Neurocrine Biosciences will be entitled to a percentage of sales by Mitsubishi Tanabe. Neurocrine Biosciences retains full commercial rights to valbenazine in North America, Europe and other countries outside of Asia.
Neurocrine Biosciences acquired the exclusive U.S. and Canadian rights to ONGENTYS® (opicapone) from Portela & CA, S.A. (BIAL) in 2017. In April 2020, ONGENTYS was approved by the U.S. FDA as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.
In October 2018, Neurocrine Biosciences entered into a research collaboration with Jnana Therapeutics aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders.
In January 2019, Neurocrine Biosciences entered into a strategic collaboration with Voyager Therapeutics focused on the development and commercialization of Voyager’s gene therapy programs, including VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined.
Xenon Pharmaceuticals Inc.
In December 2019, Neurocrine Biosciences entered into a license and collaboration agreement with Xenon to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 and three preclinical candidates, which it will have the exclusive right to further develop and commercialize. NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including focal onset epilepsy.
Neurocrine Biosciences acquired the global rights to NBI-827104 from Idorsia in May 2020. NBI-827104 is a potent, selective, orally active and brain penetrating T-type calcium channel blocker, being developed to treat pediatric patients with Continuous Spike and Wave During Sleep (a rare pediatric epileptic encephalopathy) and other potential indications, including essential tremor. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
In June 2020, Neurocrine Biosciences entered into a strategic collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Specifically, Neurocrine Biosciences received an exclusive license for seven Takeda pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.